Medifocus Inc. Announces Units Offering

Medifocus Inc. (Medifocus) (TSX VENTURE:MFS)(OTCQX:MDFZF) announces, subject to
regulatory approval, a non-brokered private placement of up to 26,666,666 units
(the Units) at a price of $0.15 per Unit for anticipated gross proceeds of up to
$4,000,000 (the Offering). Each Unit is comprised of one common share (a Common
Share) and one Series C Common Share purchase warrant. Each Series C Common
Share purchase warrant will entitle the holder to purchase one additional Common
Share at a price of $0.20 for a period of 24 months following the completion of
the Offering. If, at any time prior to July 8, 2014, the daily volume weighted
average trading price of the Common Shares on the TSX Venture Exchange exceeds
$0.75 for at least 10 consecutive trading days, Medifocus may, within 30 days of
such occurrence, give an expiry acceleration notice to the holders of warrants
and, if it does so, the warrants will, unless exercised, expire on the 30th day
after the expiry acceleration notice is given.


The proceeds of this Offering will be primarily used to commercialize the newly
acquired Prolieve(R) line of business, for working capital and to continue
Medifcous' pivotal phase III clinical trials using Medifocus Microfocus APA 1000
System for the treatment of breast cancer (including all related professional
expenses). 


About Medifocus

Medifocus owns a patented microwave focusing technology platform (the Adaptive
Phased Array ("APA") technology), which can precisely target and control
microwave energy to cause heating in cancerous tumors anywhere in the body
reliably and repeatedly. The ability to target tumors with a precision
controlled dose of heat can be used to destroy tumors at higher temperatures, to
treat tumors in combination with chemotherapy and/or radiation at moderate
temperatures for increased effectiveness and reduced toxicity and to trigger the
targeted release of therapeutic drugs and genes at tumor sites at lower
temperatures. While the core technology has been licensed from the Massachusetts
Institute of Technology, Medifocus has further refined the precision of the
microwave focusing and control ability and developed a commercial system
dedicated exclusively for the treatment of Breast Cancer. Please visit
www.medifocusinc.com for more details.


Forward-Looking Statements and Information

This news release contains "forward-looking statements" and "forward-looking
information", which may not be based on historical facts. Forward-looking
statements and forward-looking information, include, but are not limited to,
information and statements with respect the proceeds of the Offering and the
expected use of the proceeds. Forward-looking statements are frequently
characterized by words such as "plan," "expect," "project," "intend," "believe,"
"anticipate", "estimate" and other similar words, or statements that certain
events or conditions "may" or "will" occur. Forward-looking statements are based
on the opinions and estimates of management at the date the statements are made.
Such forward-looking statements and forward-looking information involve known
and unknown risks, uncertainties and other factors that may cause the actual
results events or developments to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements or forward-looking information. These factors should be considered
carefully and readers are cautioned not to place undue reliance on such
forward-looking statements and forward-looking information. Except as required
by applicable securities laws, the Company disclaims any obligation to update
any such factors or to publicly announce the results of any revisions to any of
the forward-looking statements or forward-looking information contained herein
to reflect future results, events or developments.

AlliancePharma Inc. (TSXV:APA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024